Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 7/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.31 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754453 | 0.88 | HTT (0.46) | TLR2HTTPLA2G2CCYP3A4P2RY10 | |
| SCHEMBL25754451 | 0.84 | NOS3 (0.34) | TLR2NOS3NOS1NOS2 | |
| SCHEMBL25754456 | 0.83 | NOS3 (0.33) | TLR2HTTNOS3NOS1NOS2 | |
| SCHEMBL25754455 | 0.78 | HSD17B10 (0.37) | HTTNOS3NOS1NOS2CYP3A4 | |
| SCHEMBL25754215 | 0.71 | CES2 (0.37) | TLR2PAOX | |
| SCHEMBL25754217 | 0.71 | CES2 (0.37) | TLR2HTTPAOX | |
| SCHEMBL25754459 | 0.71 | CYP3A4 (0.34) | TLR2CYP3A4 | |
| SCHEMBL25754480 | 0.70 | HTT (0.40) | TLR2HTTCYP3A4SPHK1 | |
| SCHEMBL25754209 | 0.69 | CES2 (0.38) | PAOX | |
| SCHEMBL4018310 | 0.69 | GSR (0.52) | TLR2ITGB3ITGA2BGSRNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | TLR2 1633/4885HTT 916/4885ITGB3 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.